Step 1 topics → Reproductive → Menopausal Hormone Therapy (HRT)

Menopausal Hormone Therapy (HRT)

USMLE Step 1 trap: Fails to recognize that unopposed estrogen HRT requires a progestin in women with an intact uterus. Estrogen-only HRT is contraindicated in women with an intact uterus because unopposed estrogen causes endometrial hyperplasia and increases endometrial cancer risk; progestin must be added.

Menopausal hormone therapy is one of those topics where the details matter enormously — the exam doesn't just ask 'what does HRT do?' It asks you to pick the right regimen for the right patient, weigh benefits against real risks, and recognize when HRT is the wrong choice. USMLE Step 1 tests this through both direct recall (which patients need progestin added?) and clinical vignette reasoning (a post-menopausal woman with hot flashes and a history of breast cancer — now what?). The core framework is simple but students consistently botch it under pressure.

The biggest trap is thinking HRT is a single thing. It's not. Estrogen-only and combined estrogen-progestin therapy have meaningfully different risk profiles, and which one you use depends entirely on whether the uterus is present. The second trap is overgeneralizing: students who know HRT increases breast cancer risk sometimes assume progestin is the culprit and that removing it fixes the problem — but that's backwards. Combined therapy carries more breast cancer risk than estrogen alone, and estrogen-only post-hysterectomy may even be slightly protective.

USSMLE Step 1 also tests whether you understand what HRT is actually for. Hot flashes, genitourinary syndrome of menopause (vaginal atrophy, dyspareunia), and osteoporosis prevention — those are the real indications. Cardiovascular protection is not a primary indication and should not appear in your answer as a reason to start HRT. Know the benefits, know the risks, know the contraindications, and always anchor your decision on uterus status first.

From real student decks
73%have cards covering this topic
54%have mature cards

Common misconceptions

Common mistake
Wrong: Estrogen-only HRT is safe to use in women with an intact uterus.
Right: Estrogen-only HRT is contraindicated in women with an intact uterus because unopposed estrogen causes endometrial hyperplasia and increases endometrial cancer risk; progestin must be added.
Estrogen drives endometrial proliferation — without progestin to oppose it, the endometrium keeps growing, leading to hyperplasia and eventually adenocarcinoma. This is not a theoretical risk; it's why the estrogen-only arm of the Women's Health Initiative excluded women with a uterus. If the uterus is present, you must add a progestin to any systemic estrogen regimen. Estrogen-only HRT is only appropriate after hysterectomy.
Common mistake
Wrong: Combined estrogen-progestin HRT reduces breast cancer risk because progestin is protective.
Right: Combined estrogen-progestin HRT increases breast cancer risk with prolonged use; estrogen-only HRT (post-hysterectomy) has a less clear or possibly reduced breast cancer risk.
Progestin does not protect breast tissue — it actually increases the proliferative signal there. Combined estrogen-progestin HRT carries a higher breast cancer risk than estrogen alone, which is the opposite of what most students assume. Estrogen-only HRT (used only post-hysterectomy) has a more nuanced and possibly reduced breast cancer risk compared to combined therapy. The take-home: adding progestin solves the endometrial problem but worsens the breast cancer risk.
Common mistake
Gap: Missing that HRT's primary indication is symptom relief, not cardiovascular prevention
HRT effectively treats vasomotor symptoms (hot flashes), genitourinary syndrome of menopause, and prevents osteoporosis, but is not first-line for cardiovascular protection.
HRT's evidence-based indications are symptomatic: controlling vasomotor symptoms (hot flashes, night sweats) and treating genitourinary syndrome of menopause (vaginal dryness, atrophy, dyspareunia). It also prevents bone loss and reduces osteoporotic fracture risk. Cardiovascular protection was once thought to be a benefit, but randomized trial data (WHI) showed HRT does not reduce cardiovascular events and may increase risk in older women — so it is not used for cardiac protection. Symptom relief is the primary reason to prescribe it.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a menopausal patient's uterine status, identify whether estrogen-only or combined estrogen-progestin HRT is appropriate — and explain why the wrong choice causes harm.
  2. Recognize the benefits of HRT (vasomotor symptom relief, genitourinary syndrome treatment, osteoporosis prevention) and distinguish these from non-indications like primary cardiovascular protection.
  3. Identify absolute and relative contraindications to HRT, including estrogen-sensitive cancers (breast, endometrial), active thromboembolic disease, and unexplained vaginal bleeding.
  4. Understand the differential breast cancer risk between estrogen-only versus combined HRT and why adding progestin does not provide protection against breast cancer.

Can you avoid these mistakes?

A 52-year-old woman with an intact uterus is started on estrogen-only HRT for hot flashes. What is the most serious long-term risk you are exposing her to, and what should be done differently?
A post-menopausal woman who had a hysterectomy 5 years ago wants HRT for severe vasomotor symptoms. She asks if adding progestin would make her regimen safer overall. How do you respond, and what does her uterine status mean for breast cancer risk?
Which of the following is a primary, evidence-supported indication for HRT: (A) prevention of cardiovascular disease, (B) treatment of hot flashes and genitourinary syndrome of menopause, (C) reduction of breast cancer risk, (D) first-line treatment of osteoporosis in all post-menopausal women?
A 58-year-old woman with a history of estrogen-receptor-positive breast cancer asks about HRT for intolerable hot flashes. What is the most important contraindication to address here, and what non-hormonal alternatives exist for her symptoms?

Related topics

Menopause (FSH ↑↑, Estradiol ↓) Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →